

UT20 Rec'd PCT/PTO 15 APR 2003

15 April 2003


IN THE UNITED STATES PATENT AND TRADEMARK
OFFICE AS THE DESIGNATED/ELECTED OFFICE (DO/EO/US)

In re/ Application of George H. Searfoss III, Marco F. Pagnoni,
Yuri D. Ivashchenko, Kun Guo and Kenneth L. Clark
U.S. Application No. 10/018,030
Based on International Application No. PCT/US00/09178
Filed April 6, 2000
Variants of TRAF2 Which Act as an
Inhibitor of TNF-aAlpha (TNF α) Signaling Pathway
(Attorney Docket No. P22,816A USA)

RECEIVED
APR 24 2003
TECH CENTER 1600/2900

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on 15 April 2003, in an envelope marked "Express Mail Post Office to Addressee," Mailing Label No. EV 161247371US addressed to: Commissioner for Patents, Box PCT, **Attention: DO/EO/US**, Washington, DC, 20231.


Lois Shatz

Commissioner for Patents
Box PCT
Attention: DO/EO/US
Washington, D.C., 20231

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR § 1.97(b)


Sir:

Applicants hereby request that the enclosed documents be considered as part of the examination of the above-identified application. These documents were cited in the specification of the application, International Search Report mailed on 30 August 2000 and/or the International Preliminary Examination Report mailed on 26 February 2001.

A list on Form PTO-A820 (also Form PTO-1449) is attached hereto. A copy of each information item is enclosed herewith.

Respectfully submitted,
SYNNESTVEDT & LECHNER LLP

By: _____



Patrick J. Kelly
Registration No. 34,638

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950
Telephone: 215-923-4466
Facsimile: 215-923-2189

PJK:mdb

Enclosures

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number
		P22,816A USA	10/018,030
		Applicant(s) George H. Searfoss, III et al.	
		Filing Date	Group Art Unit
		October 26, 2001	To be determined

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
C	SONG, et al., Tumor Necrosis Factor (TNF)-mediated Kinase Cascades: Bifurcation of Nuclear Factor-kB and c-jun N-terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-associated Factor 2, Proc. Natl. Acad. Sci., Volume 94, pages 9792-9796, September 1997, Immunology
D	MIN, et al., TNF Initiates E-Selectin Transcription in Human Endothelial Cells Through Parallel TRAF-NF-kB and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 Pathways, The Journal of Immunology, 1997, Volume 159, Pages 3508-3518
E	BRYANT, et al., Cardiac Failure in Transgenic Mice with Myocardial Expression of Tumor Necrosis Factor-a, Circulation Volume 97, No. 14, Pages 1375-81, April 1998
F	KUBOTA, et al., Dilated Cardiomyopathy in Transgenic Mice with Cardiac-Specific Overexpression of Tumor Necrosis Factor-a, Circulation Research, Volume 81, No. 4, pages 627-35, October 1997
G	Ursula Muller-Werdan et al., Cardiodepression by Tumor Necrosis Factor-alpha, European Cytokine Network, Volume 9, Issue 4, Pages 689-92, December 1998
H	Aukrust, et al., Cytokine Network in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy, The American Journal of Cardiology, Volume 83, No. 3, Pages 376-82, 1999
I	Palermo et al., Transgenic Remodeling of the Contractile Apparatus in the Mammalian Heart, Circulation Research, Volume 78, No. 3, Pages 504-9, March 1996
J	Shani, Moshe, Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature, Volume 314, No. 21, Pages 283-86, March 1985
K	Jeyaseelan, et al., A Novel Cardiac-Restricted Target for Doxorubicin: Carp, A Nuclear Modulator of Gene Expression in Cardiac Progenitor Cells and Cardiomyocytes, The Journal of Biological Chemistry, Volume 272, No. 36, Pages 22800-8, September 5, 1997

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.